Agenovir is commercialising technology developed at Stanford University and Howard Hughes Medical Institute that could eliminate currently untreatable viruses.
US-based biotechnology startup Agenovir has raised $10.6m in series A capital from a syndicate including pharmaceutical company Celgene.
The round was led by venture capital firm Data Collective and also featured Lightspeed Venture Partners, assorted angel investors and a range of unnamed investors.
Agenovir is using nucleases – a type of enzyme that cuts bonds in nucleic acids – to fight viruses by attacking them at the DNA-level, and the technology may potentially be able to cure currently untreatable conditions.
…
